OptimizeRx (OPRX) Net Equity Issued and Repurchased (2014 - 2021)

OptimizeRx (OPRX) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $70.7 million in Q1 2021.

• For the quarter ending Q1 2021, Net Equity Issued and Repurchased changed N/A year-over-year to $70.7 million; the trailing twelve-month figure through Dec 2021 stood at $70.7 million (changed N/A YoY), and the FY2021 full-year result was $70.7 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased advanced to $70.7 million in Q1 2021, from $1.0 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $70.7 million in Q1 2021 to a low of -$1.3 million in Q4 2018.
• A 4-year average of $11.7 million and a median of $328673.5 in 2018 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased plunged 54.25% in 2019 and surged 406.53% in 2020, its largest moves.
• Tracing OPRX's Net Equity Issued and Repurchased over 4 years: stood at -$1.3 million in 2018, then increased by 17.45% to -$1.1 million in 2019, then jumped by 198.03% to $1.0 million in 2020, then surged by 6662.2% to $70.7 million in 2021.
• Business Quant data shows OPRX's Net Equity Issued and Repurchased at $70.7 million in Q1 2021, $1.0 million in Q3 2020, and -$1.1 million in Q4 2019.